Explain the Controversy About the New Sublingual Sufentanil (Dsuvia)
You'll hear about a new sublingual sufentanil tablet (Dsuvia, deh-SOO-vee-uh) for acute pain management.
It was initially developed for battlefield use.
But FDA approval of this potent opioid during the opioid epidemic...with its easy-to-administer dosage form...is stirring up concerns.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote